US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Principal U.S. Small-Cap Multi-Factor ETF

53.09

+0.14000.26%

Post-market: 53.02-0.0700-0.13%16:04 EDT

Volume:63.76K

Turnover:3.38M

Market Cap:750.69M

PE:58.99

High:53.48

Open:53.22

Low:52.64

Close:52.95

Loading ...

Overview Company News Filings

Press Release: Constellation's Deal With Calpine Approved by New York Public Service Commission

Synergia Energy’s Cambay PSC Project Advances with New Drilling Plans

PSC Corporation Ltd Conducts AGM with Electronic Voting

Chemomab Therapeutics Advances Nebokitug for PSC Treatment

Press Release: Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

The ex-JC teacher who started a Tiong Bahru cafe with viral doughnuts and baked a Crazy Rich Asians wedding cake

West Virginia American Water Files Rate Request Driven by More Than $300 Million of Investment

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Press Release: Shell Plc 1st Quarter 2025 Unaudited Results

Press Release: Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

EZCORP Reports Second Quarter Fiscal 2025 Results

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Announces New Medical and Clinical Appointments

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Conrad Asia Energy Unit Signs Settlement Deal with South East Asian Energy Company

MT Newswires Live

Artesian Water Company, Inc. Files Application with Delaware Public Service Commission for Increase in Customer Rates

PSC Corporation Ltd Appoints New Joint Company Secretary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","market":"US","secType":"STK","nameCN":"Principal U.S. Small-Cap Multi-Factor ETF","latestPrice":53.09,"timestamp":1751054400000,"preClose":52.95,"halted":0,"volume":63763,"hourTrading":{"tag":"盘后","latestPrice":53.02,"preClose":53.09,"latestTime":"16:04 EDT","volume":4,"amount":212.36,"timestamp":1751054653618},"delay":0,"floatShares":14140001,"shares":14140001,"eps":0.9,"marketStatus":"Market Closed","change":0.14,"latestTime":"06-27 16:00:00 EDT","open":53.22,"high":53.48,"low":52.64,"amount":3382275.75,"amplitude":0.015864,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.9,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":52.95,"sharesOutstanding":14140001,"nav":52.894132,"aum":749891717.47,"dividendRate":0.007534,"bidAskSpread":0.001786,"postHourTrading":{"tag":"盘后","latestPrice":53.02,"preClose":53.09,"latestTime":"16:04 EDT","volume":4,"amount":212.36,"timestamp":1751054653618},"volumeRatio":0.7598449872944438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","floatShares":14140001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7598449872944438,"shares":14140001,"dividePrice":0.4,"high":53.48,"amplitude":0.015864,"preClose":52.95,"low":52.64,"week52Low":42.36,"pbRate":"--","week52High":57.24,"institutionHeld":0,"latestPrice":53.09,"eps":0.9,"divideRate":0.007534,"volume":63763,"delay":0,"ttmEps":0.9,"open":53.22,"prevYearClose":51.27,"prevWeekClose":51.51,"prevMonthClose":51.12,"prevQuarterClose":48.5596,"fiveDayClose":51.51,"twentyDayClose":51.22,"sixtyDayClose":48.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543679222","title":"Press Release: Constellation's Deal With Calpine Approved by New York Public Service Commission","url":"https://stock-news.laohu8.com/highlight/detail?id=2543679222","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543679222?lang=en_us&edition=fundamental","pubTime":"2025-06-16 19:00","pubTimestamp":1750071600,"startTime":"0","endTime":"0","summary":"Approval advances transaction that will create America's leading reliable and clean energy provider, with coast-to-coast presence. Constellation  today announced it has received regulatory approval from the New York State Public Service Commission  for its previously announced acquisition of Calpine Corporation.The approval represents the most recent key step forward in Constellation's plans to combine the nation's largest zero-emissions nuclear fleet with Calpine's premier portfolio of low-emission natural gas and geothermal assets. The deal will establish a coast-to-coast platform capable of supporting growing demand for around-the-clock, sustainable power.Constellation Energy Corporation , a Fortune 200 company headquartered in Baltimore, is the nation's largest producer of reliable, emissions-free energy and a leading energy supplier to businesses, homes and public sector customers nationwide, including three-fourths of Fortune 100 companies. With annual output that is nearly 90% c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CEG","BK4585","CSTA.U","IE0002270589.USD","IE00BD4GTT62.SGD","LU1093756325.SGD","BK4606","IE00B19Z3B42.SGD","PSC","LU1093756168.USD","IE00BD4GTV84.USD","BK4588","IE00B7SZLL34.SGD","IE00B19Z3581.USD","IE00BD4GTW91.USD","BK4081","CPN"],"gpt_icon":0},{"id":"2540768687","title":"Synergia Energy’s Cambay PSC Project Advances with New Drilling Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2540768687","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540768687?lang=en_us&edition=fundamental","pubTime":"2025-06-02 14:57","pubTimestamp":1748847440,"startTime":"0","endTime":"0","summary":"Oilex Ltd ( ($GB:SYN) ) has issued an announcement. Synergia Energy Ltd announced that its joint venture partner, Selan Exploration, has secured a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/synergia-energys-cambay-psc-project-advances-with-new-drilling-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/synergia-energys-cambay-psc-project-advances-with-new-drilling-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2537763187","title":"PSC Corporation Ltd Conducts AGM with Electronic Voting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537763187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537763187?lang=en_us&edition=fundamental","pubTime":"2025-05-23 17:48","pubTimestamp":1747993718,"startTime":"0","endTime":"0","summary":"PSC Corporation Ltd ( ($SG:DM0) ) has shared an announcement. PSC Corporation Ltd held its Annual General Meeting on April 25, 2025, at its locatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/psc-corporation-ltd-conducts-agm-with-electronic-voting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/psc-corporation-ltd-conducts-agm-with-electronic-voting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC","BK4209","AGM","BK4195","BK4229","SG"],"gpt_icon":0},{"id":"2536337252","title":"Chemomab Therapeutics Advances Nebokitug for PSC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2536337252","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536337252?lang=en_us&edition=fundamental","pubTime":"2025-05-17 11:53","pubTimestamp":1747454034,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q1 earnings. Here is a breakdown of the information Chemomab Therapeutics Ltd. presented to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-advances-nebokitug-for-psc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-advances-nebokitug-for-psc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","PSC","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2535844435","title":"Press Release: Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535844435","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535844435?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:00","pubTimestamp":1747310400,"startTime":"0","endTime":"0","summary":"--Reported Positive 48-Week Data from SPRING Trial--Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis--. --Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial--. --These Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to Potentially Become the First FDA-Approved Treatment for PSC--. --Cash Runway Extended to the Second Quarter of 2026--. --Company Advancing Multiple Partnering Options for Executing the Nebokitug Program--. TEL AVIV, Israel, May 15, 2025  -- Chemomab Therapeutics Ltd., , a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2025, and provided a corporate update.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DM0.SI","PK","BK4007","BK4232","INN","BK4539","BK4139","CMMB","R","BK4181","BK4218","BK4022","PSC","LENZ","BK6053"],"gpt_icon":0},{"id":"2534212602","title":"The ex-JC teacher who started a Tiong Bahru cafe with viral doughnuts and baked a Crazy Rich Asians wedding cake","url":"https://stock-news.laohu8.com/highlight/detail?id=2534212602","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534212602?lang=en_us&edition=fundamental","pubTime":"2025-05-09 11:09","pubTimestamp":1746760140,"startTime":"0","endTime":"0","summary":"Judy Koh left her teaching career to pursue baking, founding Creative Culinaire in 2000 and Caffe Pralet in 2006, which is now run by her son Timothy Chia.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--OG8qO2g_--/c_crop,h_1200,w_1600,x_0,y_0/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/06/befunky-collage_31.jpg?itok=yWqmuHVm","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--OG8qO2g_--/c_crop,h_1200,w_1600,x_0,y_0/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/06/befunky-collage_31.jpg?itok=yWqmuHVm"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/dining/caffe-pralet-crazy-rich-asians-5111536","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2533957568","title":"West Virginia American Water Files Rate Request Driven by More Than $300 Million of Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2533957568","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533957568?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:05","pubTimestamp":1746475500,"startTime":"0","endTime":"0","summary":"Request reinforces company’s commitment to providing safe, clean, and reliable service. \"Our commitment to long-term investments in our water and wastewater systems helps ensure we deliver high-quality service across the Mountain State,\" said Scott Wyman, President of West Virginia American Water. \"These ongoing investments are vital for providing safe, clean, and reliable service to the communities we serve. They demonstrate our dedication to the public health and safety of those communities.\". The PSC’s 300-day statutory rate review process offers multiple opportunities for customer involvement. Customers can participate through written comments, attendance at public hearings, and consumer advocacy organizations that participate in the proceedings. For more information on the company’s rate proposal and to learn how customers may participate in this process, visit westvirgi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/west-virginia-american-water-files-200500440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2125910336.SGD","LU2413666699.HKD","LU2506952410.USD","IE00BD4GTW91.USD","LU2506952337.HKD","LU2413666004.HKD","LU1917777945.USD","LU2229751404.USD","LU1620156213.USD","LU2413666426.HKD","LU2089279066.USD","LU0347712357.USD","LU2106854487.HKD","BK4172","LU2543165471.USD","LU1543694498.USD","LU1620156130.USD","LU2023250504.SGD","AWK","PSC","LU1923621640.USD","BK4588","IE00BD4GTT62.SGD","LU2413665964.HKD","LU1721427968.SGD","LU2125910179.SGD","LU1165135440.EUR","LU1721428347.USD","LU1721428933.USD","LU1596574779.USD","IE00BD4GTV84.USD","LU2477742899.HKD","LU1974910355.USD","LU2240825500.USD","LU2211815571.USD"],"gpt_icon":0},{"id":"2533374689","title":"GENFIT to Present Latest ACLF Research at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533374689","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533374689?lang=en_us&edition=fundamental","pubTime":"2025-05-05 13:30","pubTimestamp":1746423000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , May 5, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver  Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community.I.PostersSix posters have been accepted for presentation at EASL Congress mainly covering several of GENFIT’s assets positioned in ACLF and, including, GENFIT’s latest work on Real-World data in ACLF.ACLFPoster #1: Intraperitoneal administration of investigational drug VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosisPoster: FRI-172. Author/s: Jonel Trebicka, Arun J. Sanyal, Thierry Artzner, William Bernal, Joan Clària, Javier Fernández, Lise Lotte Gluud, Jennifer Lai, Jacqueline O’Leary, Pierre-Emmanuel Rautou, Deb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-present-latest-aclf-research-053000310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USA","APHP","GNFT","BK4108","GNFTF","CCA","BK4139","PBC","PSC","KOL"],"gpt_icon":0},{"id":"2532675028","title":"Press Release: Shell Plc 1st Quarter 2025 Unaudited Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532675028","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532675028?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:00","pubTimestamp":1746165600,"startTime":"0","endTime":"0","summary":"Q1 2025      Q4 2024      Q1 2024    %                         Reference. Income attributable to Shell plc shareholders, compared with the fourth quarter 2024, reflected lower exploration well write-offs, lower operating expenses and higher Products margins.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","BK4201","LU0098860793.USD","LU0300736062.USD","BK4140","LU2236285917.USD","LU1162221912.USD","SPDC","BK4588","PSC","LU0278409577.USD","BK4585","FID","LU0300736492.USD","SHEL"],"gpt_icon":0},{"id":"2531222034","title":"Press Release: Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531222034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531222034?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:33","pubTimestamp":1746016380,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025. Mirum Pharmaceuticals, Inc.  today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress.LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. , in Europe , and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus.To learn more about Mirum, visit mirumpharma.com and fo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","03160","BK4588","MIRM","R","HST","BK4516","BK4099","PSC","BK4520","X","BK4604","BK4585","BK4555","TM","BK4181","BK4022","BK4139","BK4006","BK4232"],"gpt_icon":0},{"id":"2531266914","title":"GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266914?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:10","pubTimestamp":1745871000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , April 28, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor, highlighting favorable safety profile and significant efficacy in Primary Sclerosing Cholangitis , at the European Association for the Study of the Liver  on May 10, 2025 at 11.15 CET.Pascal Prigent, CEO of GENFIT, commented: “We continue to be very pleased with Ipsen’s commitment to developing elafibranor, and the results from the ELMWOOD Phase 2 trial further reinforce our belief in elafibranor’s potential to address serious liver diseases.”ABOUT PSCPSC is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, which can lead to liver damage and eventually liver failure. The exact cause of PSC is unknown, but it is often associated with other autoimmune conditions, such as inflam","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-positive-breaking-phase-2-201000577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","BK4183","LU0979878070.USD","CCA","LU1878469433.USD","USA","LU1559883803.SGD","LU1242518931.SGD","ELF","LU0566484027.USD","EC","BK4588","GGT","LU1242518857.USD","BK4599","LU0053671581.USD","GNFTF","PSC","BK4201","GNFT","PBC","ALT"],"gpt_icon":0},{"id":"2531784262","title":"EZCORP Reports Second Quarter Fiscal 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531784262","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531784262?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"Record Q2 PLO & Revenues Drive Strong Increase in Profitability. AUSTIN, Texas, April 28, 2025  -- EZCORP, Inc. , a leading provider of pawn transactions in the United States and Latin America, today announced results for its second quarter ended March31, 2025.Unless otherwise noted, all amounts in this release are in conformity with U.S. generally accepted accounting principles  and comparisons shown are to the same period in the prior year.Dilutedearnings per share increased 14% to $0.33. On an adjusted basis, dilutedearningsper share increased 21% to $0.34.CEO COMMENTARY AND OUTLOOKLachie Given, Chief Executive Officer, stated, “Our team delivered another impressive quarter of operational and financial performance, highlighted by record Q2 PLO, which drove strong growth in revenue and pawn service charges. Persistent inflation and economic pressure continue to impact value-conscious consumers who are increasingly turning to us for short-term cash and secondhand goods. Our strengthen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ezcorp-reports-second-quarter-fiscal-200500863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","EZPW","PSC"],"gpt_icon":0},{"id":"2530409113","title":"Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409113?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers. Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Other Fibro-Inflammatory Conditions. Second EASL 2025 Poster Reports that Pharmacokinetic and Pharmacodynamic Data from the Phase 2 Spring Trial Demonstrates Effective and Dose-Dependent Antibody-Target Engagement. The second abstract presents an analysis of the pharmacodynamics and pharmacokinetics  of nebokitug and CCL24 using patient data from the Phase 2 SPRING trial in patients with PSC.2 PK analyses indicated dose-proportional increases in the concentration of nebokitug with steady-state","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-reports-positive-clinical-data-120000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4218","PSC","BK4139","CMMB","PK"],"gpt_icon":0},{"id":"2529647669","title":"Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2529647669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529647669?lang=en_us&edition=fundamental","pubTime":"2025-04-24 14:14","pubTimestamp":1745475240,"startTime":"0","endTime":"0","summary":"Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options. Patients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase . Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placebo. PARIS, FRANCE, 24 April 2025 Ipsen  will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver  congress as an oral presentation, on 10 May at 11.15 CET. For the first time data highlighting the potential of elafibranor in treating people living with primary sclerosing cholangitis  will be presented. PSC is a rare liver disease that currently has no approved treatment options.Patients on elafibranor also had stabilization i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-elafibranor-primary-sclerosing-cholangitis-061400283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","IPSEY","LU0053671581.USD","LU1559883803.SGD","GGT","BK4599","LU1242518857.USD","EC","LU0566484027.USD","LU0979878070.USD","BK4585","BK4588","BK4183","ELF","BK4007","PBC","IPSEF","LU1242518931.SGD","BK4139","LU1878469433.USD","BK4201","PSC"],"gpt_icon":0},{"id":"2529806511","title":"Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806511?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:00","pubTimestamp":1745236800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 21, 2025  -- Chemomab Therapeutics, Ltd., , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug  for the treatment of patients with primary sclerosing cholangitis  will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis : The Spring Study. Paul Pockros, MD, Director, Liver Disease Scripps Clinic and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-therapeutics-present-nebokitug-clinical-120000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","LENZ","BK4139","CMMB","BK4007"],"gpt_icon":0},{"id":"2527490299","title":"Chemomab Announces New Medical and Clinical Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2527490299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527490299?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience. Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial inPSC, Assumes Chief Development Officer Role. Dr. Weiner commented, “I welcome the opportunity to rejoin Chemomab at this exciting time for the company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other fibro-inflammatory diseases. These are challenging times for o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-announces-medical-clinical-appointments-120000196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","CMMB","BK4139"],"gpt_icon":0},{"id":"2527216355","title":"Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527216355","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527216355?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:30","pubTimestamp":1744633800,"startTime":"0","endTime":"0","summary":"LIVMARLI Tablet formulation approved for patients with Alagille Syndrome  and Progressive Familial Intrahepatic Cholestasis . FOSTER CITY, Calif., April 14, 2025----Mirum Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has approved a new tablet formulation of LIVMARLI  for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis .\"The approval of LIVMARLI in tablet form provides a meaningful additional treatment option for patients with ALGS and PFIC. It allows flexibility for patients and physicians, with the liquid dosing used by the youngest patients and a convenient one-tablet per dose option for older patients,\" said Peter Radovich, president and chief operating officer at Mirum. \"We have had tremendous success with LIVMARLI since its launch and we hope that the availability of the tablet will provide convenience that positively impacts patients’ lives.\". LIVMARLI tablets are plan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-livmarli-now-fda-approved-123000969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4505","BK4520","BK4079","BK4139","BK4532","PSC","IBAT","BSEP","BK4006","MIRM","X","FSV","BK4588","BK4516","ALGS"],"gpt_icon":0},{"id":"2526378509","title":"Conrad Asia Energy Unit Signs Settlement Deal with South East Asian Energy Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2526378509","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526378509?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:56","pubTimestamp":1744250178,"startTime":"0","endTime":"0","summary":"Conrad Asia Energy,  its subsidiary, and West Natuna Exploration , operator of Duyung Production Sharing Contract , signed a settlement agreement with Coro Energy and Coro Energy Duyung , according to a Thursday filing with the Australian bourse.The agreement outlines the transfer of Coro Duyung's 15% participating interest in the Duyung PSC to WNEL, bringing WNEL's total interest to 91.5%, the filing said.Coro Duyung is also released from any obligation to pay cash calls, and WNEL will receive a total cash consideration of $300,000 from Coro Energy.The agreement is contingent on approval from Indonesia's Ministry of Energy and Mineral Resources and shareholder approval, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRD.AU","BK7095","DM0.SI","BK7142","PSC.AU","BK6053","PSC"],"gpt_icon":0},{"id":"2525737496","title":"Artesian Water Company, Inc. Files Application with Delaware Public Service Commission for Increase in Customer Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2525737496","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525737496?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:05","pubTimestamp":1743797100,"startTime":"0","endTime":"0","summary":"NEWARK, Del., April  04, 2025  (GLOBE NEWSWIRE) -- Artesian Water Company, Inc. (“Artesian”), a subsidiary of Artesian Resources Corporation (Nasdaq: ARTNA), filed an application with the Delaware Pub","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3056193/30413/en/Artesian-Water-Company-Inc-Files-Application-with-Delaware-Public-Service-Commission-for-Increase-in-Customer-Rates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSC"],"gpt_icon":0},{"id":"2524919565","title":"PSC Corporation Ltd Appoints New Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524919565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524919565?lang=en_us&edition=fundamental","pubTime":"2025-04-01 17:43","pubTimestamp":1743500594,"startTime":"0","endTime":"0","summary":"The latest announcement is out from PSC Corporation Ltd ( ($SG:DM0) ). PSC Corporation Ltd has announced the appointment of Ms. Siau Kuei Lian as J...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/psc-corporation-ltd-appoints-new-joint-company-secretary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/psc-corporation-ltd-appoints-new-joint-company-secretary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC","BK4185","JYNT","SG","BK4209"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSC\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"PSC","amount":0.110318,"announcedDate":"2025-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-03"},{"date":"2024-12-27","symbol":"PSC","amount":0.07952,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2024-12-31"},{"date":"2024-10-01","symbol":"PSC","amount":0.1071,"announcedDate":"2024-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-01","defaultRemindTime":1727789400000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-10-01","currency":"USD","dateTimestamp":1727755200000,"payDate":"2024-10-03"},{"date":"2024-07-01","symbol":"PSC","amount":0.09909,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-07-01","name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-07-01","currency":"USD","dateTimestamp":1719806400000,"payDate":"2024-07-03"},{"date":"2024-04-01","symbol":"PSC","amount":0.096411,"announcedDate":"2024-03-28","type":"dividend","market":"US","newRecordDate":"2024-04-02","defaultRemindTime":1711978200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","recordDate":"2024-04-04","payableDate":"2024-04-02","currency":"USD","dateTimestamp":1711944000000,"payDate":"2024-04-04"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSC\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-04","value":0.0954808,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-07","value":0.073752,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-10","value":0.078723,"currency":"USD"},{"executeDate":"2017-10-02","recordDate":"2017-10-03","paymentDate":"2017-10-05","value":0.053592,"currency":"USD"},{"executeDate":"2018-04-02","recordDate":"2018-04-03","paymentDate":"2018-04-05","value":0.083439,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSC\",market:\"US\",delay:false,,,undefined,":{}}}